Treatment of graft-versus-host disease with naturally occurring T regulatory cells

BioDrugs

Volumn 27, Issue 6, 2013, Pages 605-614

  Trzonkowski, Piotr ^a   Dukat Mazurek, Anna ^a   Bieniaszewska, Maria ^a   Marek Trzonkowska, Natalia ^a   Dobyszuk, Anita ^a   Juåcińska, Jolanta ^b   Dutka, Magdalena ^a   Myåliwska, Jolanta ^a   Hellmann, Andrzej ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Regional Center of Blood Donation and Treatment Hoene Wro skiego   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; GRAFT VS HOST DISEASE; HUMANS; IMMUNE TOLERANCE; QUALITY OF LIFE; T-LYMPHOCYTES, REGULATORY;

EID: 84891869098     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0050-5     Document Type: Review

References (73)

1. Billingham RE. The biology of graft-versus-host reactions. Harvey Lec. 1966;62:21-40.
2. Blattman JN, Antia R, Sourdive DJ, Wang X, Kaech SM, Murali-Krishna K, Altman JD, Ahmed R. Estimating the precursor frequency of naive antigen-specifi c CD8 T cells. J Exp Med. 2002;195:657-64. (Pubitemid 34461511)
3. Vallera DA, Carroll SF, Snover DC, Carlson GJ, Blazar BR. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier. Blood. 1991;77(1):182-94.
4. Sprent J, Schaefer M, Korngold R. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. II. Protective effects of L3T4+ cells in anti-class II GVHD. J Immunol. 1990;144(8):2946-54. (Pubitemid 20149464)
5. Mowat AM, Sprent J. Induction of intestinal graft-versus-host reactions across mutant major histocompatibility antigens by T lymphocyte subsets in mice. Transplantation. 1989;47(5):857-63. (Pubitemid 19139128)
6. McGuinness UM, Baines MG. Augmented natural killer cell activity during neonatal graft-versus-host disease is of predominantly donor origin. Immunobiology. 1989;180(1):101-5. (Pubitemid 20011527)
7. Ferrara JL, Guillen FJ, van Dijken PJ, Marion A, Murphy GF, Burakoff SJ. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation. 1989;47(1):50-4. (Pubitemid 19049143)
8. Trzonkowski P, Zaucha JM, Mysliwska J, Balon J, Szmit E, Halaburda K, Bieniaszewska M, Mlotkowska M, Hellmann A, Mysliwski A. Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients. Med Oncol. 2004;21(1):81-94. (Pubitemid 38491334)
9. Korngold R, Sprent J. Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med. 1987;165(6):1552-64. (Pubitemid 17087907)
10. Blazar BR, Taylor PA, Sehgal SN, Vallera DA. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood. 1994;83(2):600-9.
11. Knobloch C, Dennert G. Loss of F1 hybrid resistance to bone marrow grafts after injection of parental lymphocytes. Demonstration of parental anti-F1 T killer cells and general immunosuppression in the host. Transplantation. 1988;45(1):175-83.
12. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90(8):3204-13. (Pubitemid 27444217)
13. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301-5. (Pubitemid 34303674)
14. Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C, Ferrara JL, Teshima T. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172:7393-8. (Pubitemid 38747600)
15. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-47. (Pubitemid 46697905)
16. + regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490-500.
17. + Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol. 2009;39(11):3091-6.
18. Edinger M, Hoffmann P. Regulatory T cells for the prevention of graft-versus-host disease: professionals defeat amateurs. Eur J Immunol. 2009;39(11):2966-8.
19. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol. 1998;10:371-8. (Pubitemid 28182093)
20. + T cells. Immunity. 2006;25:249-59. (Pubitemid 44224144)
21. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev. 2006;212:131-48. (Pubitemid 44116705)
22. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192(2):303-10. (Pubitemid 30470313)
23. + regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood. 2005;105(12):4871-7. (Pubitemid 40807316)
24. + T helper cells. Eur J Immunol. 2004;34(5):1303-11. (Pubitemid 39256009)
25. + T regulatory cells. J. Immunol. 2005;175(12):7889-97. (Pubitemid 41798349)
26. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med. 1992;176:1595-9.
27. + regulatory cells that control intestinal inflammation. J Exp Med. 2000;192(2):295-302. (Pubitemid 30470312)
28. Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012;12(1):210-7.
29. Chen Y, Fukuda T, Thakar MS, Kornblit BT, Storer BE, Santos EB, Storb R, Sandmaier BM. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy. 2011;13(10):1269-80.
30. + and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol. 2004;112(3):258-67. (Pubitemid 39078701)
31. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005;202(8):1075-85. (Pubitemid 41464501)
32. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21(4):589-601. (Pubitemid 39370513)
33. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol. 2005;174(4):1783-6. (Pubitemid 40223916)
34. + T cells. Mol Immunol. 2010;47(4):678-84.
35. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol. 2006;177(10):6780-6. (Pubitemid 44715042)
36. + T cells. Nat Immunol. 2007;8(12):1353-62. (Pubitemid 350131172)
37. + T regulatory cells. J Immunol. 2006;177(8):5115-21. (Pubitemid 44527582)
38. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055-66.
39. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra43.
40. + regulatory T cells. Blood. 2011;118(8):2342-50.
41. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401-6. (Pubitemid 34875668)
42. + regulatory T lymphocytes. Nat Med. 2008;14(1):88-92.
43. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-99. (Pubitemid 34875667)
44. + regulatory T cells protects from lethal acute GVHD. Blood. 2005;105(5):2220-6. (Pubitemid 40731816)
45. + immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol. 2006;176(2):1266-73. (Pubitemid 43099732)
46. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112(11):1688-96. (Pubitemid 38063726)
47. MiltenyiBiotec. Clinical applications. Immunotherapy. 2012. https://www.miltenyibiotec.com/en/Clinical-applications/Immunotherapy/ Treg-cells.aspx. Accessed 25 Jun 2013.
48. BDBioscience. Regulatory T cells: essential regulators of the immune system. BD Biosci News Lett. 2009; ISBN: 23-10562-00.
49. Trzonkowski P, MyÅliwska J, Pawelec G, MyÅliwski A. From bench to bedside and back - the SENIEUR Protocol and the efficacy of influenza vaccination in the elderly. Biogerontology. 2009;10(1):83-94.
50. + T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans: impact of immunosenescence. Clin Immunol. 2006;119(3):307-16.
51. + T-cells. Mech Ageing Dev. 2010;131(2):96-104.
52. highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care. 2012;35(9):1817-20.
53. Marek-Trzonkowska N, MyÅliwec M, Siebert J, Trzonkowski P. Clinical application of regulatory T cells in type 1 diabetes. Pediatr Diabetes. 2013. doi: 10.1111/pedi.12029.
54. Trzonkowski P, Szaryńska M, MyÅliwska J, MyÅliwski A. Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. Cytometry A. 2009;75(3):175-88.
55. + regulatory T cells for clinical trials. Biol Blood Marrow Transplant. 2006;12(3):267-74. (Pubitemid 43273711)
56. Godfrey WR, Ge YG, Spoden DJ, Levine BL, June CH, Blazar BR, Porter SB. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood. 2004;104(2):453-6. (Pubitemid 38900028)
57. Milward K, Issa F, Hester J, Figueroa-Tentori D, Madrigal A, Wood KJ. Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells. Transplantation. 2013;95(1):85-93.
58. low/neg Treg expansion for the purpose of clinical application. Int Immunopharmacol. 2013. doi: S1567-5769(13)00058-1.
59. Marek N, Bieniaszewska M, Krzystyniak A, Juscinska J, Mysliwska J, Witkowski P, Hellmann A, Trzonkowski P. The time is crucial for ex vivo expansion of T regulatory cells for therapy. Cell Transplant. 2011;11-12:1747-58.
60. Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;18(3):83ra41.
61. + regulatory T cells. Blood. 2005;105(12):4743-8. (Pubitemid 40807298)
62. Grzanka J, Leveson-Gower D, Golab K, Wang XJ, Marek-Trzonkowska N, Krzystyniak A, Wardowska A, Mills JM, Trzonkowski P, Witkowski P. FoxP3, Helios, and SATB1: roles and relationships in regulatory T cells. Int Immunopharmacol. 2013. doi: S1567-5769(13)00046-5.
63. + immunoregulatory cells. J Immunol. 2001;167:1137-40. (Pubitemid 32703105)
64. Marek N, Krzystyniak A, Ergenc I, Cochet O, Misawa R, Wang LJ, Goła̧b K, Wang X, Kilimnik G, Hara M, Kizilel S, Trzonkowski P, Millis JM, Witkowski P. Coating human pancreatic islets with CD4(+)CD25(high)CD127(-) regulatory T cells as a novel approach for the local immunoprotection. Ann Surg. 2011;254(3):512-8.
65. Canavan JB, Afzali B, Scottà C, Fazekasova H, Edozie FC, Macdonald TT, Hernandez-Fuentes MP, Lombardi G, Lord GM. A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood. 2012;119(8):57-66.
66. - T regulatory cells. Clin Immunol. 2009;133(1):22-6.
67. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921-8.
68. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061-70.
69. Komanduri KV, Champlin RE. Can Treg therapy prevent GVHD? Blood. 2011;117(3):751-2.
70. Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol. 2011;23:679-84.
71. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018-28. (Pubitemid 44343545)
72. Golab K, Leveson-Gower D, Wang XJ, Grzanka J, Marek-Trzonkowska N, Krzystyniak A, Trzonkowski P, Witkowski P. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol. 2013. doi: S1567-5769(13)00043-X.
73. + T regulatory cells in humans. Int Immunopharmacol. 2013. doi: S1567-5769(13)00057-X.